[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fvIghVFeI2DbOgA4eYpp0FMaVk8rBwGps6zT05Lt9iuQ":8,"$fRSS4dMy4x7IqWY9bLxjKhtAlCNT-NpshbRSNyazX4g4":55,"$feo1F64P0AQPnplJK1Xb-Dkv_JB4nNzXliVsfuaS8AG0":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},65660,868966,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//Sn4y5XFopDyAUMV8myik3Yz75ketV11V.png","王坚楠","浙江大学医学院附属第一医院","甲状腺乳腺外科","主治医师",45,0,"乳腺癌术后靶向治疗：帕妥珠曲妥珠单抗使用指南","","https://ystcdn.venuertc.com/venue/AI/c00f6e6c-b243-4cbf-b311-f9d38a955e08.jpg","\u003Cdiv class=\"perjeta-material-container\">\n  \u003Ch1 id=\"material_title\" class=\"perjeta-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">乳腺癌术后靶向治疗：帕妥珠曲妥珠单抗使用指南\u003C/h1>\n  \u003Cdiv class=\"perjeta-lead\">\n    \u003Cp>说到靶向治疗，帕妥珠曲妥珠单抗（英语名：Pertuzumab，常见品牌Perjeta）是近年来临床上应用较多的一类单克隆抗体药物，主要用于辅助乳腺癌患者术后进一步巩固疗效。本文将带你关注用这类药物时真正不能忽略的细节，包括用法、剂型、剂量、注意事项、不良反应、相互作用、以及存储等7大关键点，让您用药更安心。🌸\u003C/p>\n  \u003C/div>\n  \n  \u003Csection class=\"perjeta-block\" style=\"background:linear-gradient(90deg,#f0f7fa 40%,#f7fafd 100%);\">\n    \u003Ch2 class=\"perjeta-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"perjeta-emoji\">🔬\u003C/span>01 帕妥珠曲妥珠单抗的基本认识\u003C/h2>\n    \u003Cul class=\"perjeta-info-list\">\n      \u003Cli>成分名称：\u003Cstrong>帕妥珠曲妥珠单抗（Pertuzumab）\u003C/strong>。\u003C/li>\n      \u003Cli>常见剂型：\u003Cstrong>注射剂\u003C/strong>，多以静脉滴注方式应用，部分制剂为皮下注射剂型（如10ml/次，便于临床操作）。\u003C/li>\n      \u003Cli>药品类别：\u003Cstrong>单克隆抗体类靶向药物\u003C/strong>，专一性结合和阻断HER2受体蛋白。\u003C/li>\n      \u003Cli>常用于乳腺癌术后的辅助治疗环节，强调与其他药物（如曲妥珠单抗、化疗药物）联合使用。\u003C/li>\n    \u003C/ul>\n    \u003Cp class=\"perjeta-note\">正确做法：每次用药需明确剂型规格、配药方法，每一步都要遵循医生及药师指导，切勿自行更改用药方式。\u003C/p>\n  \u003C/section>\n  \n  \u003Csection class=\"perjeta-block\" style=\"background:linear-gradient(90deg,#f5f8fa 70%,#f5fafa 100%);\">\n    \u003Ch2 class=\"perjeta-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"perjeta-emoji\">🎯\u003C/span>02 作用机制：靶向HER2，阻断异常信号\u003C/h2>\n    \u003Cul class=\"perjeta-info-list\">\n      \u003Cli>帕妥珠曲妥珠单抗通过\u003Cstrong>特异性结合HER2蛋白\u003C/strong>的胞外结构，使HER2无法与其他同类受体（如HER3）结合，拦截了刺激细胞异常生长和分裂的信号。\u003C/li>\n      \u003Cli>同时激活免疫系统，使免疫细胞（如自然杀伤细胞）主动“识别”并清除被标记的异常细胞。\u003C/li>\n      \u003Cli>这种作用属于靶向精确打击，对正常细胞影响较小。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"perjeta-highlight\">这种机制确保药物对特定目标产生作用，从根本上阻断异常信号通路，是现代抗癌药物的新思路（参考：Robert Hakim, 2024）。\u003C/div>\n  \u003C/section>\n  \n  \u003Csection class=\"perjeta-block\" style=\"background:linear-gradient(90deg,#fcfcfa 60%,#f3f6f8 100%);\">\n    \u003Ch2 class=\"perjeta-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"perjeta-emoji\">🕒\u003C/span>03 正确用法用量：怎么用最安全？\u003C/h2>\n    \u003Cul class=\"perjeta-info-list\">\n      \u003Cli>\n        用药方案：首剂常见为\u003Cstrong>840mg\u003C/strong>静脉点滴，滴注时间60分钟以上；随后每3周一次，\u003Cstrong>维持量为420mg/次\u003C/strong>，点滴30-60分钟。\n      \u003C/li>\n      \u003Cli>\n        部分制剂可用于皮下注射，如10ml/次（参阅实际案例），由专业医护人员操作。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>滴注速度慢，必须在专业机构进行\u003C/strong>，这样可及时发现反应，保障安全。\n      \u003C/li>\n      \u003Cli>\n        推荐联用：常与另一种单抗药物（曲妥珠单抗）及化疗药（例：多西他赛）联合使用，不建议单独应用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>绝不自行调整剂量\u003C/strong>，每次用药前须复查心功能与体重，必要时根据实际情况调整。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"perjeta-case\">\n      \u003Cspan class=\"perjeta-emoji\">📑\u003C/span>\n      \u003Cstrong>用药案例：\u003C/strong>一位72岁女性患者（身高153cm，体重48kg）术后随访期间应用皮下注射单抗制剂10ml/次，按专业医护流程操作，期间未见明显过敏反应。\n    \u003C/div>\n    \u003Cp class=\"perjeta-note\">需要注意：每次输注都要留观，避免出现急性输液反应。\u003C/p>\n    \u003Cp class=\"perjeta-note\">如漏打一针，\u003Cstrong>不可擅自补打\u003C/strong>，务必与主治医师商量处理。\u003C/p>\n  \u003C/section>\n\n  \u003Csection class=\"perjeta-block\" style=\"background:linear-gradient(90deg,#f5f7f6 85%,#faf7f8 100%);\">\n    \u003Ch2 class=\"perjeta-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"perjeta-emoji\">👩‍⚕️\u003C/span>04 用药监测与配合检查要点\u003C/h2>\n    \u003Cul class=\"perjeta-info-list\">\n      \u003Cli>\n        \u003Cstrong>心功能检测：\u003C/strong>每3个月监测心脏射血分数（EF），以发现早期心脏影响（如左心功能减退）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>化验配合：\u003C/strong>如定期查血常规、肝肾功能、电解质等，保障联合化疗期间全身状况稳定。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>输液期间监控：\u003C/strong>留意体温、脉搏、呼吸等生命体征，及时识别过敏反应。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"perjeta-highlight\">正确做法：配合医生完成每次随访与检查，是安全完成整个疗程的关键环节。\u003C/div>\n    \u003Cdiv class=\"perjeta-case\">\n      \u003Cspan class=\"perjeta-emoji\">📝\u003C/span>\n      \u003Cstrong>用药体会：\u003C/strong>临床上有患者每次输注前主动配合心超检查，发现异常即暂停用药，避免了严重不良反应。\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"perjeta-block\" style=\"background:linear-gradient(90deg,#f9fcfb 50%,#f9fafb 100%);\">\n    \u003Ch2 class=\"perjeta-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"perjeta-emoji\">⚠️\u003C/span>05 主要不良反应及处理方法\u003C/h2>\n    \u003Cul class=\"perjeta-info-list\">\n      \u003Cli>\n        \u003Cstrong>最常见副作用：\u003C/strong>腹泻、恶心、呕吐、疲劳、皮肤红疹、脱发等。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>需警惕副作用：\u003C/strong>心力衰竭、严重的输液反应（如气短、胸闷、心悸）、过敏反应（皮疹、面部肿胀、呼吸困难）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>紧急处理：\u003C/strong>如出现呼吸困难、剧烈胸痛等情况，应立即停止用药并找医生处理。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>持续性腹泻：\u003C/strong>属较常见副作用，发生率可达约66%；出现严重腹泻须补液并根据医生建议停止或调整用药（Swain, S.M. et al, NEJM 2013）。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"perjeta-highlight\">遇到副作用不要害怕，大多可逆。严重不适应立刻就医，不要自己停药或减药。\u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"perjeta-block\" style=\"background:linear-gradient(90deg,#fbfaf9 80%,#f7f9fa 100%);\">\n    \u003Ch2 class=\"perjeta-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"perjeta-emoji\">⛔\u003C/span>06 用药禁忌与特殊人群调整\u003C/h2>\n    \u003Cul class=\"perjeta-info-list\">\n      \u003Cli>\n        \u003Cstrong>明确禁忌：\u003C/strong>对本品或配方中任何成分过敏者\u003Cstrong>严禁使用\u003C/strong>。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>孕妇和哺乳期女性：\u003C/strong>动物试验已证实对胎儿有害，孕期/哺乳期\u003Cstrong>绝不可用\u003C/strong>。育龄妇女应采取有效避孕措施。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>老年人：\u003C/strong>通常无需特别调整剂量，但更要密切监测心功能。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>肝肾功能障碍：\u003C/strong>尚无充分相关数据，建议用药前先评估肝肾功能，必要时咨询药师或医生。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"perjeta-case\">\n      \u003Cspan class=\"perjeta-emoji\">👵\u003C/span>\n      \u003Cstrong>用药案例：\u003C/strong>有位老年患者在使用帕妥珠曲妥珠单抗时，医生根据其基础体重和既往病史选择标准方案，并加强心脏监测，全程安全完成所有疗程。\n    \u003C/div>\n    \u003Cp class=\"perjeta-note\">特别提醒：计划生育、接受疫苗接种或近期手术者，务必在用药前主动告知医生。\u003C/p>\n  \u003C/section>\n\n  \u003Csection class=\"perjeta-block\" style=\"background:linear-gradient(90deg,#f5fafb 60%,#f7fafd 100%);\">\n    \u003Ch2 class=\"perjeta-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"perjeta-emoji\">🔄\u003C/span>07 药物相互作用与注意事项\u003C/h2>\n    \u003Cul class=\"perjeta-info-list\">\n      \u003Cli>\n        与\u003Cstrong>其他抗肿瘤药\u003C/strong>（如曲妥珠单抗、多西他赛）常规联合应用时，应严格按照医嘱调整相关剂量与疗程。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>不建议同时使用活疫苗\u003C/strong>，因影响免疫反应及增加感染风险。\u003C/li>\n      \u003Cli>\n        所有处方药物、非处方药物及草本补充剂用药前均要主动告知医生，避免潜在药物相互作用。\u003C/li>\n      \u003Cli>\n        \u003Cstrong>手术前后：\u003C/strong>计划手术者请提前报备治疗药物，便于制定综合调理方案。\u003C/li>\n      \u003Cli>\n        如有任何药物过敏或以往用药反应史，也需事先说明。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"perjeta-highlight\">正确做法：所有用药调整、增减，都要提前征询药师/医生指导。\u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"perjeta-block\" style=\"background:linear-gradient(90deg,#fcfbfc 75%,#edf5f7 100%);\">\n    \u003Ch2 class=\"perjeta-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"perjeta-emoji\">💡\u003C/span>08 储存方法与药品管理\u003C/h2>\n    \u003Cul class=\"perjeta-info-list\">\n      \u003Cli>\n        \u003Cstrong>最佳储存温度：\u003C/strong>2°C-8°C冷藏保存（不宜冷冻）。避免高温、直射阳光及强光环境。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>药品开封后：\u003C/strong>如未使用完，须在说明书规定的时间内尽快使用完毕，切勿二次复用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>药品效期：\u003C/strong>请务必关注外包装标识的有效期，超过有效期严禁继续使用。\n      \u003C/li>\n      \u003Cli>\n        未用药品统一回收处理，不可随意丢弃以免污染环境。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"perjeta-highlight\">冷链管理很重要，家庭储存建议直接交由专科医疗机构代为管理。\u003C/div>\n  \u003C/section>\n  \n  \u003Csection class=\"perjeta-block\" style=\"background:linear-gradient(90deg,#f5f6fb 60%,#f7f5fc 100%);\">\n    \u003Ch2 class=\"perjeta-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"perjeta-emoji\">🌈\u003C/span>09 提高生活质量的小妙招\u003C/h2>\n    \u003Cul class=\"perjeta-info-list\">\n      \u003Cli>\n        \u003Cstrong>合理补水：\u003C/strong>出现轻微腹泻时，需额外饮水，必要时配合营养补充。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>均衡饮食：\u003C/strong>增加蛋白质、新鲜蔬果摄入，减轻药物引起的消化道反应。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>适度锻炼：\u003C/strong>在医生指导下进行简易的散步或拉伸，有助于恢复体能。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>心理疏导：\u003C/strong>积极与医护团队沟通，在需要时寻求心理支持资源。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"perjeta-info\">\n      正确做法：依靠团队力量，科学应对副作用，保持良好心态，为疗程加分。\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"perjeta-summary\" style=\"background:linear-gradient(90deg,#fbfaf9 80%,#f7f9fa 100%);\">\n    \u003Ch3 class=\"perjeta-h3\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"perjeta-emoji\">📝\u003C/span>结语：用药安全，疗效更稳\u003C/h3>\n    \u003Cp>帕妥珠曲妥珠单抗的优势在于定位精准、与多种方案协同、对生活质量影响较可控。但心脏监测、严格操作流程、储存管理、联合用药调整等环节都必须落实。请一定牢记最重要的两点：\u003Cstrong>安全操作不松懈，所有用药调整必须告知医生\u003C/strong>。如遇不良反应或任何疑问，请及时与医疗团队沟通。用药规范，效果更好，风险更低。\u003C/p>\n  \u003C/section>\n  \n  \u003Csection class=\"perjeta-references\">\n    \u003Ch3 class=\"perjeta-h3\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"perjeta-emoji\">📚\u003C/span>参考文献\u003C/h3>\n    \u003Col class=\"perjeta-ref-list\">\n      \u003Cli>\n        Swain, S. M., Baselga, J., Kim, S. B., et al. (2013). Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. \u003Ci>New England Journal of Medicine, 368\u003C/i>(8), 734-746. \u003Ca href=\"https://www.nejm.org/doi/full/10.1056/NEJMoa1209021\" target=\"_blank\">Link\u003C/a>\n      \u003C/li>\n      \u003Cli>\n        Robert Hakim, PharmD. (2024). Perjeta (Pertuzumab): A Promising Medication for HER2-Positive Breast Cancer. AmeriPharma Specialty Care. \u003Ca href=\"https://ameripharmaspecialty.com/perjeta-pertuzumab-for-her2-positive-breast-cancer/\" target=\"_blank\">Link\u003C/a>\n      \u003C/li>\n    \u003C/ol>\n  \u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n.perjeta-material-container {\n  background: #fafcfd;\n  margin: 0 auto;\n  max-width: 850px;\n  padding: 40px 32px 30px 32px;\n  border-radius: 18px;\n  box-shadow: 0px 6px 28px 0px rgba(206,212,218,0.12),0px 1px 2px 0px rgba(178,178,178,0.07);\n  font-family: \"Segoe UI\", \"PingFang SC\", \"Microsoft YaHei\", Arial, sans-serif;\n  font-size: 18px;\n  color: #2a3440;\n}\n\n.perjeta-title {\n  font-size: 2.2em;\n  font-weight: 700;\n  margin-bottom: 14px;\n  letter-spacing: 1.5px;\n  color: #416c9a;\n  text-align: center;\n}\n\n.perjeta-lead {\n  color: #5b78a3;\n  font-size: 1.05em;\n  margin-bottom: 28px;\n  text-align: center;\n  line-height: 1.8;\n  background: #f4f7fb;\n  border-radius: 10px;\n  padding: 16px 15px;\n}\n\n.perjeta-block {\n  margin-bottom: 28px;\n  padding: 28px 22px 20px 22px;\n  border-radius: 18px;\n  box-shadow: 0px 2px 10px 0px rgba(125,160,190,0.04);\n}\n\n.perjeta-h2 {\n  font-size: 1.32em;\n  font-weight: 600;\n  color: #2878bb;\n  margin-bottom: 11px;\n  letter-spacing: 0.5px;\n  display: flex;\n  align-items: center;\n  gap: 7px;\n}\n\n.perjeta-h3 {\n  font-size: 1.12em;\n  font-weight: 600;\n  color: #486285;\n  margin-bottom: 9px;\n  display: flex;\n  align-items: center;\n  gap: 7px;\n}\n\n.perjeta-emoji {\n  font-size: 1.1em;\n  margin-right: 4px;\n}\n\n.perjeta-info-list {\n  padding-left: 20px;\n  margin: 0 0 13px 0;\n  list-style: disc inside;\n  line-height: 1.86;\n}\n\n.perjeta-note, .perjeta-highlight {\n  background: #eaf5ff;\n  border-left: 5px solid #3399ea;\n  color: #255784;\n  padding: 8px 14px 8px 13px;\n  border-radius: 6px;\n  font-size: 0.98em;\n  margin-top: 8px;\n  margin-bottom: 0.75em;\n}\n\n.perjeta-highlight {\n  background: #fefff4;\n  border-left: 5px solid #c0ca5e;\n  color: #5f7536;\n}\n\n.perjeta-case {\n  margin-top: 10px;\n  background: #fcf1e7;\n  color: #885d20;\n  border-left: 5px solid #f6b760;\n  font-size: 0.99em;\n  padding: 8px 14px 8px 14px;\n  border-radius: 6px;\n  margin-bottom: 8px;\n}\n\n.perjeta-info {\n  background: #f7f9f2;\n  color: #5d6c42;\n  font-size: 0.98em;\n  padding: 8px 15px;\n  border-radius: 6px;\n  margin-top: 7px;\n  margin-bottom: 7px;\n  border-left: 5px solid #c0ca5e;\n}\n\n.perjeta-summary {\n  margin-top: 36px;\n  background: #f4f7fa;\n  border-radius: 14px;\n  padding: 22px 18px 18px 18px;\n}\n\n.perjeta-references {\n  margin-top: 34px;\n  padding: 18px 14px 15px 14px;\n  background: #e5ecf4;\n  border-radius: 12px;\n}\n\n.perjeta-ref-list {\n  font-size: 0.98em;\n  color: #2a3440;\n  margin-left: 17px;\n  padding-left: 0;\n}\n\n@media (max-width: 640px) {\n  .perjeta-material-container {\n    max-width: 100%;\n    padding: 20px 6px 8px 6px;\n    font-size: 16px;\n  }\n  .perjeta-title {\n    font-size: 1.32em;\n  }\n  .perjeta-block {\n    padding: 14px 6px 9px 7px;\n    margin-bottom: 20px;\n  }\n}\n\u003C/style>\n\n","\u003Cdiv class=\"perjeta-material-container\">\n  \u003Ch1 id=\"material_title\" class=\"perjeta-title\" style=\"colo",523,"2025-09-04 11:36:41","帕妥珠曲妥珠单抗, 乳腺癌, 靶向治疗, 辅助治疗, 不良反应","本文深入解读帕妥珠曲妥珠单抗的使用要点，涵盖用法、剂量、注意事项等，助力乳腺癌患者安全用药，提高生活质量。","2025-09-08 14:01:58",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]